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1. Introduction
It is a well-known fact that effectiveness of oncotherapy in brain tumors remains under the
expectations in comparison to anaplastic tumors of other organs. Knowing the very modest
survival rates enormous efforts of neuro-oncological researches has been made, but only
partial success is produced. Beside the extremely high proliferation rate of high grade glio‐
ma cells researches established the highly intensive invasiveness and angiogenesis as the
main reasons of treatment failure. In this chapter the main molecular mechanisms of brain
tumor invasion and angiogenesis will be discussed followed by the hopeful treatment possi‐
bilities that are already in studies and will be achievable in the near-future.
2. General a spects of glioma invasion
Malignant gliomas are the most common primary brain tumors. They are associated with
the shortest survival time explained by their early recurrence due to their deep invasion of
the normal brain, which makes them practically impossible to remove completely. Invasive
anaplastic gliomas are almost invariably fatal, recurring close to the resection margin in al‐
most all cases. Interestingly, primary brain tumors have a strong tendency to invade their
environment, but with rare exceptions, do not metastasize outside the brain. [1-3].
To understand the invasion behaviour of gliomas, the cellular and molecular events of peri‐
tumoral infiltration have to be discussed. The most important medium for this process is the
extracellular matrix (ECM). The ECM comprises a considerable proportion of the normal
brain volume. The extracellular space (ECS) of the healthy brain tissue volume is approxi‐
matley 20%. The extracellular volume fraction in the majority of primary brain tumors is sig‐
nificantly increased, representing about 48% of the total tumor tissue volume especially in
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high grade gliomas. The structure and compounds of the ECM of the brain tissue have
many specific differences from other human organs. The ECM of the brain contains mainly
macromolecules like glycosaminoglycans (GAGs) and proteoglycans (PGs), and only mod‐
erately express fibrillary glycoproteins (e.g. collagens, fibronectin, elastin or reticulin). The
compounds of ECM glycoproteins play a crucial role in peritumoral invasion forming struc‐
tural elements for cellular attachment and migration. There is much evidence that ECM
components can modulate brain tumor growth, proliferation, and invasion by many differ‐
ent mechanisms. Thus extracellular matrix plays a pivotal role in the tumorous infiltration of
the surrounding tissue. The presence and functions of hyaluronic acid (hyaluronan, HA),
PGs and various types of GAGs have already been intensively investigated to clarify the
molecular mechanisms of invasion, and a positive correlation has been established many
times. To allow cell adhesion and migration, the ECM components interact with specific re‐
ceptors on the cell membrane, such as integrins, CD44, or CD168. Some proteases and syn‐
thases also strongly influence invasiveness because of their capacity to alter the actual levels
of the ECM molecules or to degrade the pericellular network. [4-16]
Using the ECM macromolecules to their active movement, glioma cells infiltrate the enviro‐
ment and form it similar to the tumor tissue. The process of the peritumoral invasion de‐
pends on the confrontation zone of the tumor cells and the non-neoplastic cells and ECM.
Glioma cells express mainly adhesion receptors and proteases, while host cells produce
macromolecules to maintain original structure and to inhibit invading cell movement. Since
brain ECM has no strong fibrillar, collagen-rich network, the brain parenchyma remains
soft, that can not hinder significantly the migration of tumor cells.
In case of glial cell tumors there are two main factors that significantly promote peritumoral
infiltration. First is the normal structure of the brain parenchyma composed mainly by tracts
in the white matter and basement membranes, which are suitable for guiding cell migration.
Second is the increased ability of glia cells to migration. Both factors are special for the brain
and they can be easily understood knowing the connection of development, structure and
function. [17, 18]
From neuro-oncological point of view the increased glioma cell mobility and extensive peri‐
tumoral infiltration leads to the following problems:
a. A. Total extirpation of a low grade tumor is not an easy and evident technical tool of
therapy. This is one main reason why these tumors are “semi-benign” tumors. Thus in
spite of the macroscopically radical surgical removal, the recurrence rate of these tu‐
mors is very high, and full recovery is not a general event.
b. B. In case of high grade tumors, neither open surgery, nor stereotactic radiosurgery can
achieve radical tumor removal. This experience can explain the local recurrence that ap‐
pears in almost every case.
c. C. Local chemotherapeutical treatment (intraparenchymal or post operatively adminis‐
tered intracavital drug) has low effectiveness.
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3. Molecular aspects of glioma invasion
Molecules that are responsible for the cell migration are divided in three groups:
1. Cell-membrane associated molecules (receptors and adhesion molecules).
2. Extracellular matrix (ECM) components (targets for the receptors).
3. Enzymes that are synthesizing or lysating the ECM components.
3.1. Cell-membrane associated molecules (receptors and adhesion molecules)
Molecules with evident role in peritumoral invasion are located either on the cell surface, or
form transmembrane structure. The main representatives of this group are the receptors and
adhesion molecules as detailed below.
The Ig superfamily contains molecules in the cell membrane consisted of immunoglobulin-
like and fibronectin type III domains involved in cell–cell adhesion. The superfamily in‐
cludes the integrins, a variety of cell adhesion molecules (CAMs) with distinct ligand-
binding specificities, namely ICAM (intercellular), NCAM (neural), Ep-CAM (epithelial), L1-
CAM, VCAM (vascular), ALCAM (activated leukocyte), and JAM (junctional adhesion
molecule), among others. [19]
The integrins are the most common molecules that serve for glioma cells to adhere to ECM.
These molecules are heterodimeric transmembrane glycoproteins consisting of non-cova‐
lently linked α and β chains, which both determine ligand binding strength and specificity.
Eight distinct α and 18 β chains combine to form about 24 different heterodimers. They can
interact with two groups of ligands: some of the ECM proteins, such as fibrinogen, fibronec‐
tin, vitronectin, and cell surface molecules, that are members of the immunoglobulin super‐
family. Regarding the many different heterodimers, each cell type maintains a specific and
activation-dependent integrin repertoire and consequence ligand preference. The cytoplas‐
mic integrin domains connect to signalling proteins and to the actin-cytoskeleton mediating
intracellular signal transduction and cell movement. This function definietly demonstrate
the dynamics of cell–ECM interaction as cells move along a substrate. Thus, integrins are
prominently important mediators for cell adhesion and migration. They also interact with
growth hormone receptors and contribute to cell–cell contacts due to direct interactions with
counterpart cell receptors. On the other hand, focal contacts mainly depend on the ECM-
compartment and on the cell type. Different integrins are known to be involved in that proc‐
ess. Integrin α5β1 binds to fibronectin, α6β1 or β4 binds to laminin, αvβ3 binds to
fibronectin, vitronectin and tenascin-C and α2β1 binds to fibrillar collagen. Some of the in‐
tegrins are directly connected to malignant behavior of gliomas. Neutralizing antibodies to
β1- and αvβ5-integrin lead to decreased glioma migration in vitro. It was also demonstrated,
that tenascin increases in vitro motility of human gliomas through interaction with β1-integ‐
rins. Inhibition of β1-integrins leads also to decreased motility, whereas inhibition of αv-in‐
tegrin causes increased motility. The integrin αvβ3 plays a central role in glioma invasion.
Increased expression of integrin αvβ3 results in increased motility of glioma cells with a de‐
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crease in apoptosis sensitivity. Furthermore, inhibition of integrin αvβ3 decreases glioma
cell motility. Integrins αvβ3 and αvβ6 interacting with tenascin was proved to mediate ad‐
hesion rather than migration. Expression of β5-integrin is correlated with in vitro invasive‐
ness and migration of human glioma cells. However α-actin expression and linkage of
integrins to the cytoskeleton is related to glioma aggressiveness and poor prognosis in WHO
II and III astrocytoma. [20-33]
Integrins mediate also activation of focal adhesion kinase (FAK) that associates with β1-
and β3-integrins, which can trigger FAK phosphorylation. It is a non receptor tyrosine kin‐
ase overexpressed in invasive glioma cells, and its expression correlates with tumor
recurrence and invasiveness in many tumor types. FAK is activated either by integrin medi‐
ated adhesion to ECM or by growth factor stimulation and it induces cell migration. Induc‐
tion of FAK can protect cells from apoptosis. [34-41]
The neural cell adhesion molecule (NCAM) is expressed mainly by developing neurons. It
is downregulated during embryogenesis and re-expressed again once differentiation is initi‐
ated. Overexpression of NCAM decreases glioma cell motility in vitro. In drug-resistant
glioma cell lines NCAM expression is reduced and integrin-expression is increased that help
to explain decreased chemosensitivity in invading glioma. [42- 45]
CD44 is the most important HA-receptor expressed by every nucleated cells in vertebrates.
CD44 is a transmembrane glycoprotein belonging to the immunoglobulin receptor super‐
family. Besides the standard form (CD44s), multiple splice variants encoded by variable
exons v1–10 (CD44v1–10) can be identified depending on the cell differentiation and activa‐
tion state. Interactions of CD44 with numerous other molecules, such as collagens, laminins
and fibronectin, have been proved in vitro. CD44 is consisted of four functional domains:
amino terminal domain, stem structure, transmembrane domain and cytoplasmic domain.
The amino terminal domain can link to the ECM components such as HA and other GAGs.
The stem structure domain binds the amino-terminal domain and transmembrane domain.
The transmembrane region is probable responsible for the association of CD44 with lipid
rafts. The cytoplasmic domain of CD44 is connected to the cytoskeleton via ankyrin and oth‐
er proteins that is necessary to cell adhesion and motiliy. CD44 can be cleaved to two parts,
and both the extracellular and intracellular components of CD44 promote cell migration.
CD44 also interacts with various regulatory mediators to cell signaling pathways. Through
these connections CD44 promotes MMP-mediated matrix degradation, tumor cell growth,
migration and invasion and its expression correlates well with invasion potential of glioblas‐
toma. [46-54]
The receptor for hyaluronate-mediated motility (RHAMM) is also a HA-binding protein
expressed on the cell surface and also in the cytoplasm, cytoskeleton and nucleus. Interac‐
tion of HA with RHAMM induces many cellular signaling pathways in connection to pro‐
tein kinase-C, FAK, MAP kinases, NFκB, RAS, phosphatidylinositol kinase (PI3K), tyrosine
kinases and cytoskeletal components. CD44 and RHAMM probably have redundant or
overlapping functions, but it is evident that interactions of HA with CD44 and RHAMM are
necessary for tumorigenesis and tumor progression. [55-58]
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Syndecans are a family of transmembrane heparan sulphate proteoglycans with four mem‐
bers, syndecans 1 to 4. Syndecans are co-receptors by binding their ECM ligands in conjunc‐
tion with other receptors, mainly integrins. Through their heparan sulphate side chains,
syndecans may further take part in other ligand binding, like VEGF, fibronectin and antith‐
rombin-1. Linking syndecan to fibronectin is modulated by tenascin-C. Syndecan-1, -3, and
syndecan -2, -4 bild two different structural subgroups. Syndecan-1 is expressed generally in
fibroblasts and epithelial cells (especially in keratinocytes), but normally there is only a
moderate presence in endothel and neural cells. Syndecan-3 dominates in neural cells, but
not in epithelial cells, and syndecan-4 can be found mainly in epithel cells and fibroblasts,
while it is poorly expressed by endothel and neural cells. Syndecans have four main func‐
tion: 1. activation of growth hormon receptors; 2. cell adhesion to ECM components such as
collagens type I, III, V, fibronectin, thrombospondin and tenascin; 3. cell-to-cell adhesion
(e.g. syndecan-4 and integrin linkage takes part in intercellular interactions; 4. tumor sup‐
pression (anti-invasive effect by keeping tumor cells together) or tumor progression (de‐
pending on tumor histology and growth phase). [59-62]
Cadherin superfamily is also an important group of adhesion molecules regarding glioma
invasion. Cadherins are transmembrane proteins compound of several tandemly repeated
cadherin domains that interact in calcium-dependent homophilic cell–cell contacts. The cad‐
herin superfamily consists of more than 100 different members, with E- (epithelial) and N-
(neural) and P-cadherin, most intensively expressed in epithelial and neural tissues,
respectively. Desmosomal cadherins (desmoglein and desmocollin) provide a linkage to the
intermediate filament network through connection with cytosolic proteins (desmoplakin,
plakoglobin and plakophilin). Adherens junctions play a pivotal role in embryonic develop‐
ment as well as in the maintenance of tissue architecture in adults. Cadherins are linked to
the actin-cytoskeleton network through catenins (α-, β-catenin, plakoglobin and p120ctn),
thereby providing molecular lines of communication to other cell–cell junctions and to cell-
substratum junctions. Cadherin cluster forms a transmembrane core of adherens junctions at
sites of the cell–cell contacts. During tumor progression decreased cadherin function is cor‐
related with de-differentiation, metastasis and poor prognosis. In glioblastoma N-cadherin
cleavage is regulated by ADAM-10 that promotes tumor cell migration. Furthermore, aber‐
rantly processed proN-cadherin promotes cell migration and invasion in vitro, and in hu‐
man glioma the level of proN-cadherin is elevated that directly correlates with the invasion
potential. [63-68]
Dystroglycan is a transmembrane glycoprotein expressed mainly in sceletal muscle cells,
but it can be also found in brain tissue as well. Its main function is to creat contact between
the ECM macromolecules and the intracellular cytosceleton. It is linked intracellularly to
dystrophin, a protein coded on the X-chromosome (lack of dystrophin causes the herediter
muscle disease named dystrophia musculorum Duchenne). Dystroglycan is a heterodimeric
complex consisting of non-covalently associated α and β subunits. The α-subunit connects
α2-laminin, agrin and perlecan (components of the lamina basalis), the β-subunit is the
transmembrane part that binds to dystrophin. Overexpression of dystroglycan decreased
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the growth rate of glioma cell lines so it was found to be involved in the progression of pri‐
mary brain tumors. [69-71]
3.2. Extracellular Matrix (ECM) components (targets for the receptors)
Various components of brain ECM, like GAGs and PGs are overexpressed in gliomas. These
molecules are binding sites for tumor cell receptors or they can inhibit cell migration, so
they take an important part in peritumoral glioma invasion, and consequently could also
serve as targets for anti-tumor therapy.
Proteoglycans (PGs) are composed of a protein core and glycosaminoglycan side chains
(GAGs). GAGs are carbohydrate polymers containing N-acethylglucosamine or N-acethyl‐
galactosamine and uronic acid (glycuronacid or iduronacid).
Depending on the GAG side chains the main types of PGs are chondroitin-sulphate (gly‐
curonacid  and  N-acethylgalactosamine  polymer  and  protein  core),  dermatan-sulphates
(former  name  chondroitin-sulphate-B,  composed  of  iduronacid  and  N-acethylgalactosa‐
mine  polymer  and  protein  core),  heparansulphate  (glycuronacid  and  N-sulphoglucosa‐
mine  polymer  and  protein  core)  and  keratansulphate  (galactose  and  N-
acethylgalactosamine  polymer  and  protein  core).  Hyaluronic  acid  (hyaluronan,  HA)  is
consisted of only GAGs (glycuronacid and N-acethylglucosamin polymer) that has no co‐
valent bind to a protein, so it is not a PG by definition, but due to its tight relation to the
PGs in general it is discussed together with them.
One of the most frequent adhesion glycoprotein in the ECM is fibronectin. It has a pivotal
role in cell attachment, migration, differentiation and proliferation. Although its protein
fragment is coded by only one gene, more isoform exits due to alternative splicing. The
main cell surface receptors for fibronectin are the integrins, but it can also bind collagens,
fibrin and heparan-sulphates. It is structured of two different subunits linked by disulphid
bridges to each other. Fibronectin appears in two different forms: the solubile molecule can
be found in the plasma, produced by hepatocytes, it accumulates at wessel wall damage and
has an evident role in clot-building. The insolubile form of fibronectin is expressed by fibro‐
blasts and mainly localized in the intercellular ECM. In tumor stroma production of fibro‐
nectin is reduced and its degradation is increased. Paralel to these changes on tumor cell
surface, the expression of the fibronectin receptor α5β1 integrin is also decreased. ECM com‐
ponents such as fibronectin and collagen type IV are mostly produced by the host tissue and
are associated dominantly with the vessel walls in gliomas. Fibronectin is mainly degraded
by MMP-2 that is specifically active in gliomas explaining partly the moderate presence of
extracellular fibronectin in glioma ECM. [72-74]
Another common component of the ECM is the molecular family of laminins. This glyco‐
protein has many variants, and it is the main component of lamina basalis. It is thought to
take part in cell differentiation, adhesion, migration and cell survival. Each molecule of lam‐
inin consits three different chains (α, β, and γ chain) which has 5, 4 and 3 genetic variants,
respectively. Recently at least fifteen different chain-combinations have been detected in hu‐
man tissues. In the lamina basalis laminins promote cell-to-cell linkage, and it forms a spe‐
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cific network with connection to enactin, fibronectin and perlecan. These molecules can also
bind to cell surface receptors such as integrins or dystroglycans, etc. Laminins regulate glio‐
ma cell adhesion to ECM proteins in specific manner leading to cell proliferation or cell mi‐
gration and up-regulation of laminin is associated with the invasiveness activity. [75-77]
Agrin is also an ECM forming PG with the capability to collect acetylcholin receptors. Nor‐
mally it is indispensible in developing neuromuscular junctions during embryogenesis. Ag‐
rin is secretaed at the end of the moto-neurons, and it is also a main component of
membrana basalis in various human organs taking part in cell-ECM interactions. Together
with neurocan, tenascin-C and versican it is responsible for the peritumoral infiltration of
gliomas. [78]
Hyaluronan(HA) is a non-sulphated, linear, high-molecularweight GAG. It differs evidently
of other GAGs, because of its extremely large molecular weight (103–104 kDa) composed of
10,000 or more disaccharide repeating units, the lack of sulfate groups or epimerized uronic
acid residues and because HA is synthesized at the inner face of the plasma membrane as a
free linear polymer without any protein core. It has a significant waterbinding capacity, so it
controls the water content of the brain interstitium. HA comprises a substantial fraction of
brain ECM and is involved in many physiological and pathological processes. In normal
ECM, HA sustain tissue homeostasis, biomechanical integrity, structure and some kind of
tissue cohesion. In malignant tumor tissues, HA transmit signals into cytoplasm and induces
cell proliferation, motility and invasion. HA binds tenascins, lecticans, the cell surface recep‐
tors including CD44, RHAMM or ICAM-1, which together contribute to ECM organization
and cell–matrix interaction. Through elevating the level of MMP-9 HA also promotes peritu‐
moral invasion by activating the protease system. Glial tumors have increased amounts of
HA which facilitates invasion activity of glioma cells. [79-84]
Lecticans comprise also a family of chondroitin sulphate proteoglycans with four members
(brevican, versican, neurocan, and aggrecan), whereby brevican and neurocan are brain-spe‐
cific molecules. Lecticans contain HA and tenascin binding sites and thus mediates linkage
in protein–PG-GAG networks. [85-86]
Brain enriched hyaluronan binding (BEHAB) molecule,also known as brevican, a brain-
specific chondroitin sulfate PG shows dramatic upregulation in gliomas and it is also in‐
duced during periods of increased glial cell motility in development and following brain
injury. Gliomas express unique brevican isoforms and the processing of this specific isoform
is important for its proinvasive role. In experimentally induced tumors brevican accumu‐
lates at the invasive borders and it associates with high infiltrative profiles. Furthermore,
brevican up-regulation correlates well with short survival periods of patients with high
grade gliomas. Brevican expression in gliomas is restricted to membrane localization, and its
presence in high-grade gliomas suggests that it plays a significant role in glioma progres‐
sion. Brevican promotes activation of epidermal growth factor receptor (EGFR), increases
the synthesis of cell adhesion molecules and facilitate fibronectin microfibrill presence on
the cell membrane. The effect of brevican on glioma cells motility is mediated not only via
EGFR signaling but also by fibronectin-dependent adhesion, and increased expression of
CAMs. This motogenic signals could not be worked in the normal neural ECM, where fibro‐
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nectin is almost absent but it is effective in the microenvironment of glioma cells, which co-
express large amounts of brevican and fibronectin in vivo. This interaction explains the
distinct ability of these tumors spreading in the central nervous system. Overexpression of
brain-specific isoforms of brevican proved to be correlated with ability to peritumoral inva‐
sion of gliomas. [73, 87-89]
Neurocan is a large brain specific chondroitin-sulphate PG that interacts with heparan-sul‐
phate proteoglycan (HSPG) molecules, such as syndecan-3 and glypican-1. It has influence
on cell adhesion and migration. Neurocan has two HSPG-binding domain with different af‐
finity. In cell culture neurit outgrowth is increased by C-terminal part of neurocan. HSPGs
serve also as cell-surface receptors for neurocan, and connection of neurocan to the HSPGs is
necessary for the neurit growth. It was found on clinical samples that higher expression of
neurocan is associated with the invasive activity of astrocytomas. [89-90]
The ECM glycoprotein tenascin, which forms a hexabrachion structure, can be detected in
both the ECM and the perivascular tissues of high-grade gliomas. Tenascin R, a brain-specif‐
ic member of the tenascin family comprising also tenascin C, X, and W, is a homotrimer
with both lectican and integrin binding sites forming an adhesion link between the ECM
and cells. The developed brain does not contains tenascin, but in normal brain tissue distin‐
guishable deposits of this glycoprotein can be found in the glia limitans externa, and some
tenascin was also detected in the ECS of white matter. Theres is a positive correlation be‐
tween tenascin production and the malignancy or angiogenesis of astrocytomas and there is
a prognostic utility of its immunohistochemical detection in ependymomas. The accumula‐
tion of tenascin in the ECS in high grade glial tumors can be one of the major factors leading
to the critical increase in ECS tortuosity and the simultaneous enlargement of the ECS. It has
been arised that the ECM distribution is modified at the brain-tumor zone of confrontation
and the presence of tenascin in this zone represents a negative prognostic factor in pediatric
ependymomas. Tenascin-C is overexpressed in both low and high grade astrocytomas as
well. In cultured brain-tissue tenascin-C is produced by the endothelial cells. It takes an im‐
portant part in various cellular mechanisms like heamagglutination, T-cell immunsuppres‐
sion, angiogenesis, chondrogenesis and it also has some antiadhesive effect. Tenascin
subunits contain EGF- and fibronectin-like repeated sequences that are responsible for the
growth inducing effect. Tenascin-C enhances migration of endothelial cells and phosphory‐
lation of focal adhesion kinase (FAK). Tenascin-C signaling is mainly mediated by integrin-
β1 which interacts with FAK. Tenascin-C is produced by the glioma cells rather than by the
invaded brain and it improves aggressive behaviour and invasion activity of grade II astro‐
cytoma cells in vitro and in vivo. Furthermore, expression of tenascin-C can be used as prog‐
nostic factor in grade II astrocytomas showing correlation with ability of tumor recurrence.
Beside this, low tenascin-C expression was found to be associated with prolonged average
survival time in glioblastomas and highest tenascin-C expression could be detected at the
border of the malignant gliomas. [91-104]
Versican (also known as VCAN or CSPG2), a chondroitin sulfate PG, is one of the main
components of the ECM, expressed almost in all human tissues. Versican takes part in nor‐
mal tissue development, but its increased expression can be also detected in most malignan‐
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cies. Elevated versican production occurs in either the tumor cells or the stromal cells
surrounding the tumor. Increased versican expression strongly correlates with poor out‐
comes for many different tumor types. Versican regulates a wide variety of intracellular
processes including cell adhesion, proliferation, apoptosis, migration and invasion via the
chondroitin and dermatan sulfate side chains. In addition, the versican G1 and G3 domains
can interact with various intracellular or extracellular molecules. In addition to HA, versican
associates with tenascin-R, fibulin-1 and -2, fibrillin-1, fibronectin, P- and L-selectin, and
many chemokines. It also binds to cell surface proteins including epidermal growth factor
receptor (EGFR), CD44, and integrin β1.
A number of proteinase families are capable of generating the proteolytic fragments of versi‐
can. Matrix metalloproteinase (MMP)-1, -2, -3, -7, and -9, ADAMTS-1, -4, -5 and -9 cleave
versican and generates proteolytic fragments.The accumulation of proteolytic fragments of
versican play an important role in cancer progression. The regulation of G1 and G3 versican
levels by proteases is known to be important in regulating cancer cell motility and metasta‐
sis. Through the EGF-like motifs in the G3 domain versican can stimulate cell proliferation
and its G1 domain destabilizes cell adhesion and promotes cell growth. Versican expression
is associated with a high rate of proliferation and it is localized in HA-rich tissues and also
accumulated in perivascular elastic tissues involved in peritumoral invasion. These features
of versican make it a proliferative, anti-adhesive and pro-migratory molecule that facilitates
tumor cell motility. In clinical samples the association of versican to invasiveness of astrocy‐
toma could be evidently demonstrated. On the other side, the decreased expression of versi‐
can V0 and V1 isoforms in glioma ECM can be related to the marked local invasivity and
rarity of extracranial metastasis of gliomas. [105-111]
3.3. Enzymes that are synthesizing or lysating the ECM components
Matrix metalloproteinases (MMPs) are the most common proteases that degrade ECM to
create the space for invading glioma cells. MMPs belong to the zinc-dependent endopepti‐
dase together with adamalysins, serralysins and astacins. MMPs take part in remodelling af‐
ter tissue damage, cell migration, differentiation and angiogenesis. At least 28 different
types of MMPs are identified composing a protease family that is able to degrade practically
every component of the ECM. Due to their function, MMPs also play evident role of activat‐
ing mechanism by cleavage metabolits of inactive molecules. MMPs are overexpressed in
glioma cells compared with normal brain tissue. MMP-2, MMP-3 and MMP-9 activity corre‐
lates well with glioma cell migration and invasion. [46, 112, 113]
Cathepsin-B is a cystein protease involved in protein degradation primarily within intracel‐
lular lysosomes but it takes evidently part in degradation of ECM-proteins. In order to be
able to interact with ECM proteins, the lysosomal enzyme is secreted from its intracellular
localization. Thus cathepsin B appears on the surface of glioma cells, where the enzyme can
interact with the surrounding matrix components. Cathepsin-B is overexpressed in gliomas.
Downregulation of cathepsin B in human glioma cells leads to decreased invasiveness in
matrigel-assay and coculture experiments. Furthermore, downregulation of cathepsin-L in
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human glioma cells correlates with decreased invasiveness and increased sensitivity to
apoptotic stimuli. [114-118]
4. Invasion process of tumor cells
Knowing the invasion potential of primary brain tumors, many of the molecular mecha‐
nisms of peritumoral infiltration have been already studied and some of the invasion proc‐
esses have been defined. During malignant transformation, invasiveness is determined by
the complex functions of tumor cells of distinct histological types. A four-step model of in‐
vasion has been applied, that is also valid for brain tumors. This model contains the follow‐
ing steps: 1) the tumor cells at the invasive site detach from the growing primary tumor
mass; 2) they adhere to the extracellular matrix (ECM) via specific recebptors; 3) proteases
secreted by the glioma cells locally degrade the ECM components, forming a pathway mi‐
gration into the surrounding tissue, and 4) tumor cell movement due to cytosceletal process‐
es. Each step of the peritumoral invasion requires a harmonized cooperation of numerous
molecules resulted in active cellular movement into the normal brain parenchyma. [119, 120]
The detachment of invading glioma cells from the primary tumor mass is a complex process
comprising the following steps: 1) Destabilization and disorganization of the cadherin medi‐
ated junctions that hold the primary mass together. 2) Decrease expression of cell adhesion
molecule which provides adhesion to the primary tumor mass. This leads to a reduction in
gap junction formation. Cell–cell communication is necessary for growth control and differ‐
entiation, and it is mainly achieved through gap junctions. Increased malignancy of gliomas
is accociated with reduced in situ gap junction formation, and invasion of gliomas. 3) Cleav‐
age of CD44, which anchors the primary mass to the ECM. This process is mediated by met‐
alloproteinase ADAM. [119-123]
Tumor cell adherence to the ECM components is mediated by specific cell surface or trans‐
membrane receptors like integrins binding to laminins, fibronectins and collagens or CD44
to hyaluronan.
Degradation of ECM components occurs due to the local enhancement and activation of
protease suc as MMPs, hyaluronidase, cathepsins and chondroitin suphatase.
Due to migration the glioma cell must interact with the surrounding ECM, which forms a
mechanical barrier to the cells, and serves as a substratum for traction for the moving cells.
For cell movement changes in cell morphology occur: the cell becomes polarized and mem‐
brane protrusions develop, including the extensions at the leading edge of pseudopodia, la‐
mellipodia, filopodia, and invadopodia. These extensions contain filamentous actin and
various structural and signaling molecules. The formation of membrane anchors needs cy‐
toskeletal contraction, which finally results a cell forward displacement. Glioma cell motility
and contractility also require A and B isoforms of myosin II. Myosin II is the major source of
cytoplasmic contractile force. Myosin II allows glioma cells to squeeze through pores small‐
er than their nuclear diameter, which is especially important for gliomas because the human
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brain tissue has particularly narrow extracellular spaces. The connection of ECM macromo‐
lecules and cytosceleton is mediated by dystroglycans. [69, 124]
5. The possible agents for antiinvasive therapy
Tumor cell invasion into the surrounding brain tissue is mainly responsible for the failure of
radical surgical resection and successful treatment, with tumor recurrence as microdissemi‐
nated disease. ECM related molecules and their receptors predominantly participate in the
invasion process, including the cell adhesion to the surrounding microenvironment and cell
migration. Determination of the key molecules of invasion process can help toprovide possi‐
ble targets for antiinvasive therapy. Regarding peritumoral infiltration activity of glioma
cells, the following molecules are supposed to serve as antitumor agents.
Cilengitide is a cyclic peptide targeting the RGD-motif of integrins blocking αvβ3- and
αvβ5-integrin mediated interaction between endothelial cells and ECM. By targeting these
integrins cilengitide could inhibit both glioma invasion and angiogenesis. Cilengitide causes
significant regression of glioma xenograftsand induces apoptosis in U87 glioma cells cul‐
tured on tenascin and vitronectin. In clinical trials targeting glioma invasion, in a random‐
ized phase II study cilengitide proved to be safe and was associated with a median survival
of 10 months in recurrent glioma patients. The North American Brain Tumor Consortium
(NABTC) study aimed to determine cilengitide penetration rate into GBM in human pa‐
tients. This study confirmed that cilengitide is effectively delivered into primary human
GBM tumors with good retention. The effect of combination therapy, such as cilengitide
with XRT or with another chemotherapeutic agent, is likely to be cumulative. [125-129]
Knowing the evident role of versican proteolytic fragments in cancer progression, its possi‐
ble role as target for anti-cancer therapy has been arised. Although there are only a few re‐
sults regarding anti-versican therapy in glioma patients, some possible agents are notable to
mention for their potential future role.The tyrosine kinase inhibitor genistein has been
shown to block versican expression in malignant mesothelioma cell lines and in vascular
smooth muscle cells. Versican G3 fragments facilitate cancer cell growth, invasion and meta‐
stasis through EGFR signaling. The selective EGF receptor inhibitor, AG1478 prevents G3
fragment enhanced cell growth, migration, invasion and chemical resistance in vitro. Galar‐
din, an antibody against the ADAMTS specific versican cleavage site inhibits glioma cell mi‐
gration. GM6001, a MMP and ADAMT proteases inhibitor, also decreases cancer cell
invasion and metastasis in several kinds of carcinoma. Other protease inhibitors such as cat‐
echin gallate esters, present in natural sources (green tea) selectively inhibit ADAMTS-1, -4
and -5 catabolism. [130-137]
Tumor  formation  of  the  pericellular  matrix  with  HA  and  versican  can  be  inhibited  by
treatment with HA oligomers, which can block the interaction between HA and versican,
serving as inhibitors of cancer dissemination. Furthermore, disruption of the HA CD44 in‐
teraction  with  HA  oligomers  could  also  inhibit  the  growth  of  B16F16  melanoma  cells,
Therefore the application of HA oligomers can be an effective agent for inhibiting the for‐
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mation  of  vesicant-HA-CD44  complexes,  providing  valuable  targets  against  tumor  pro‐
gression. [138-140]
Emodin (3-methyl-1,6,8-trihydroxyanthraquinone) has evident anti-invasive effect on HA-
induced glioma invasion. In glioma cells emodin inhibits the TGFbeta and FGF-2 induced
expression of syndecan-1. It decreses the expression of MMP-2 and MMP-9 at both tran‐
scriptional and translational levels suggesting that emodin can be a clinically valuable anti-
cancer agent against glioma invasion. [141, 142]
Since increased MMP levels are associated with glioma invasion and angiogenesis, marima‐
stat, an orally active drug that can reduce MMP levels in patients with gliomas could inhibit
growing of tumor. A phase II study evaluated marimastat combined with temozolomide
(TMZ) in patients with recurrent malignant glioma and good outcome was documented, but
joint and tendon pain was reported in 47% of patients. [143, 144]
6. General aspects of angiogenesis
Rapidly growing tumors need to develop their own vasculature. The hypervascularisation
of high grade gliomas can be visualized well on radioimaging and it can be a preoperative
characteristic of glioblastoma. Furthermore, glioma angiogenesis is necessary for tumor ex‐
pansion and survival, so its inhibition could be a potential tool in anti-tumor therapy.
There are two main angiogenic and invasive glioma phenotypes. Clusters of glioma cells
perform single cell infiltrations into normal parenchyma independent of vasculature. An‐
other group of glioma cells can be found around newly developed vessels in the normal
brain parenchyma near to the tumor margin. These two different angiogenic and invasive
phenotypes  are  called  angiogenesis-dependent  and  angiogenesis  independent  invasions.
High  grade  astrocytomas  content  both  invasion  phenotypes  in  a  mixture  of  subclones
present in different intratumoral regions.  Molecular mechanisms of single cell  migration
were detailed above, but the role of neo-angiogenesis forms also a very important way to
glioma expansion. [145]
In expanding, highly proliferate gliomas angiogenesis is activated when the pro-angiogenic
stimuli dominates over the anti-angiogenic stimuli. These stimuli are mediated by factors se‐
creted from glioma, endothelial or microglia cells, or arise from the extracellular matrix or
other environmental sources like hypoxia induced cell productions. The pro- and anti-angio‐
genic forces are influenced strongly by tissue hypoxia and genetic alterations. The summa‐
tion of these stimulileads to the so-called “angiogenic switch” in glioma angiogenesis.The
most effective activator of angiogenesis in brain tumors is hypoxia that downregulates anti-
angiogenic pathways and induces many pro-angiogenic ones. A well-known pathway is the
HIF-1/VEGF-A pathway, which play a significant role in endothelial cell proliferation and
migration. Another pathway mediator is interleukin-8, which is produced by microglia cells
as a reaction to hypoxia. It is important to mention, that genetic instability of high grade
gliomas provides the way of angiogenesis independently of hypoxia (such as chronic HIF
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activation via phosphoinositide 3-kinase (PI3K) or mitogenactivated protein kinase (MAPK)
pathways. [146-152]
After activating the “angiogenic switch”, the tumor produces new vessels. The modes of
new blood vessel formation in glioma occur by one of three different methods: 1) angiogene‐
sis; 2) vasculogenesis; or 3) arteriogenesis. Angiogenesis is the formation of new blood ves‐
sels by rerouting or remodeling existing tumor vessels, and is supposed to be the main
stream of neo-angiogenesis. Vasculogenesis means de novo production of blood vessels
from circulating marrow-derived endothelial progenitor cells originally as the method of
vasculature development in embryonic process. Since these progenitor cells have been also
identified in tumors, they role in tumor angiogenesis cannot be denied. Vasculogenesis is
probably regulated by tumor-secreted stromal-derived factor 1 under the control of the hy‐
poxia-induced transcription factor hypoxia-inducible factor 1α (HIF1α). Arteriogenesis is
the third mode of arteriolar networks formation representing a moderate proportion of tu‐
mor angiogenesis. [153-156]
6.1. Neoangiogenesis
The most significant way to form new blood vessels in gliomas is neoangiogenesis. Forma‐
tion of new vessels from native vessels begins with breaking down the original vessel wall.
The process of blood vessel breakdown is composed of three main phases. The first event in
forming new vessels from existing ones is the disintegration of the vessel wall. Angiopoie‐
tin-1 (Ang-1) and its receptor Tie-2 play a pivotal role in this phase. Normally, Ang-1 binds
to Tie-2 achieving a close association between pericytes and endothelial cells that is necessa‐
ry for vasculature stability. In rapidly proliferating tumors like glioblastoma, tissue hypoxia
increases and it induces Ang-2 upregulation in endothelial cells whereas Ang-1 is accumu‐
lated tumor cells. Increased Ang-2 expression, which is an antagonist of Tie-2, leads to the
initial regression of blood vessels. Beside these, matrix-metalloproteinase (MMP)-2 expres‐
sion is induced via Tie-2 signaling, and in conjunction with VEGF promotes angiogenesis.
The second phase is the breakdown of ECM to provide place for the migration of endothel
cells to form new blood vessels. Following dissolution of native vessel wall, degradation of
the vessel basement membrane and relating ECM is the necessary condition for endothelial
cells for invasion the surrounding microenvironment. MMPs play an integral role in this
phase. In case of glioma angiogenesis, the collagenases MMP-2 and MMP-9 are involved in
this process and their expression correlates with a poor prognosis in gliomas. Expression of
MMP-2 and MMP-9 is also induced by hypoxia and through their proteolytic activity inter‐
action of endothelial cells and tumor-ECM contents like VEGF and fibroblast growth factor
(FGF) occurs. [157-166]
The third phase to form new blood vessels is the migration of endothelial cells. After disso‐
lution of the basement membrane of the blood vessels and decomponent ECM, endothelial
cells begins to proliferate and migrate toward tumor cells that expresses pro-angiogenic fac‐
tors. Due to this process cell surface adhesion and migration molecules, such as integrins
and CD44 upregulates.The activated endothelial cells secrets platelet-derived growth factor
(PDGF) that induces pericytes to participate in creating a new basement membrane. For this
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reason beside migration of endothelial cells, pericyte migration also occurs as a necessary
event of vasculogenesis. [167-169]
At the end of tumor blood vessel formation a significant change occurs in the extracellular
environment, caused by increased expression of embryonic ECM molecules, such as tenas‐
cin-C. Elevation of VEGF and Ang-2 levels can be also detected, that probably explains the
leakiness and pathologic structure of the new vessels. The result of glioma angiogenesis are
highly tortuous dilated vessels and lots of small diameter vessels with alterations in endo‐
thelial cell adhesion molecule expression and disrupted basement membrane. [170-174]
7. Molecular aspects of glioma angiogenesis
Angiogenesis is mainly induced through growth hormone receptors, especially through the
vascular endothel growth factor receptor (VEGFR). This is a transmembrane receptor with
an extracellular antibody-binding domain (for vascular endothel growth factor (VEGF)) and
an intracellular tyrosin kinase domain stimulating the PI3K/Akt pathway. In tumor angio‐
genesis the effect of VEGFR can be increased either by receptor overexpression on the cell
surface or by mutation of the receptor that without a hormone-ligand or by only a moderate
ligand connection it keeps on a permanent stimulus.
Regarding glioma angiogenesis not only VEGFR but the hormone ligand VEGF has also an
evident role in the process. There are more types of VEGF. Specifically, VEGF-A is upregu‐
lated in glioblastoma and it is produced by many cell types, such as tumor cells, stromal,
and inflammatory cells. VEGF-A is primarily induced by tissue hypoxia and it regulates en‐
dothelial cell survival, proliferation, permeability and migration mainly through the VEGF-
receptor 2 (VEGFR2). VEGF can also be derived from the tumor-ECM. Beside the increased
amount of VEGF, the receptors VEGF-R1, VEGF-R2 and VEGF-R3 are upregulated on endo‐
thelial cells in glioma in comparison to normal brain. [175- 182]
Other growth factors have also influence on angiogenesis. Epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF) and platelet derived gfrowth factor (PDGF) facili‐
tates VEGF expression. The result of pathologic increased VEGF signaling in tumors is im‐
mature, highly permeable blood vessels with deteriorated blood-brain-barrier (BBB)
function and subsequent parenchymal edema. In glioma, bFGF is expressed by tumor cells
and endothelial cells but it can be also accumulated and stored in the extracellular matrix of
glioma. [183-186]
In rapidly proliferating anaplastic gliomas oxigene supply remains constantly under the ne‐
cessity, thus hypoxia remains a permanent stimuli for angiogenic factors. It seems to induce
not only the secretion of growth factors, but also interleukin-8 (Il-8), a chemokine released
by microglia, and Il-8 is expressed in adult glioma at levels correlating to tumor grade. In
glioma the interleukin-8 mediated angiogenesis is regulated by the tumor suppressor pro‐
tein ING4 through the transcription factor NFĸB. [187-189]
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Interestingly, there are some molecules involved in neuronal pattering during embryogen‐
esis  that  have  similar  functions  in  vascular  pattern  during  tumor  angiogenesis.  One  of
these molecules is the semaphorin, that induces signal pathway through neuropilins and
plexins. Neuropilins are expressed on vascular endothelial cells and function as receptors
for  VEGF.  Their  activation  leads  to  pro-angiogenic  responses  even in  the  absent  of  the
classical  VEGF-R2 signaling  and blocking neuropilin-1  can decrease  tumor  angiogenesis
and growth. [183, 190-192]
Beside growth factors and their receptors, there are some ECM components that are overex‐
pressed in glioma vessels in comparison to normal brain tissue, and have some stimulating
effect on angiogenesis. One of the most important ECM proteins with an evident role in an‐
giogenesis is tenascin-C, which is normally not expressed in the adult brain, but in glioma it
can be found at the invading tumor border in the region of angiogenesis. Tenascin-C facili‐
tates endothelial cell migration and induces VEGF expression and focal adhesion kinase
phosphorylation, which are both important for angiogenesis. Another ECM protein in‐
volved in angiogenesis is fibronectin. The oncofetal form of fibronectin is typically only ex‐
pressed during embryogenesis, but it is also produced in GBM, and it is localized to the
tumor vessels. Laminin-8 a member of the laminin family in ECM is expressed in vascular
basement membrane of GBM. Its blocking in an animal model of GBM resulted in decreased
tumor microvessel density and increased survival. Versican is also an important ECM com‐
ponent of the tumor angiogenesis process. The versican G3 domain facilitates endothelial
cell adhesion, proliferation, and migration in vitro and blood vessel formation in nude
mouse tumors. Furthermore, G3-domain expressing cells produce increased levels of fibro‐
nectin and VEGF, suggesting their common functions in angiogenesis. [193-197]
8. The possible agents for anti-angiogenic therapy
Since VEGFR play the most significant role in tumor angiogenesis, its inhibition bears the
most effective possibility for decrease tumor growth. The VEGFR is a transmembrane tu‐
mor cell  receptor,  so  blocking antibodies  could close down its  effect.  On the other  side
blocking the intracellular  tyrosine-kinase domain could also inhibit  the activation of  the
signaling pathways. The latest way came into the front in past few years, when small-mo‐
lecular tyrosine kinase inhibitors proved to be effective in vitro against glioma cell lines.
Beside these, blocking the VEG-factor itself can also definitely decrease the stimulating ef‐
fect of the receptor.
8.1. VEGF-blocking
The most known VEGF neutralizing antibody is the bevacizumab that is already a possible
tool of the oncotherapy for glioblastoma. In recurrent glioma patients treated with bevacizu‐
mab combined with the chemotherapy agent irinotecan the median survival can be pro‐
longed. As the result of a significant antitumor effect 63% radiographic response, 6-month
progression-free survival in 32% of GBM patients could be achieved. Based on these favora‐
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ble observations further clinical trials have been initiated to combine bevacizumab with te‐
mozolomide, the current standard of care for newly diagnosed glioblastoma patients.
Another clinical trial suggests that the presence of tumor hypoxia markers predicts probable
radiographic response and better survival of patients treated with combinant chemotherapy
of bevacizumab and irinotecan. Gliomas treated with bevacizumab often appear as nonen‐
hancing infiltrating laesions on MRI proving the reduced vascularity beside the ongoing in‐
vasion, so induction of anti-angiogenic therapy combined with anti-invasive therapy seems
to be a possible treatment method in the future. [198-203]
8.2. VEGF-receptor blocking
Anti-angiogenic therapy with VEGF receptor inhibitor sunitinib normalizates tumor vascu‐
lature, so it elevates intratumoral level of temozolomide due to the improved vessel func‐
tions. Cediranib is a pan-VEGFR tyrosine kinase inhibitor, while enzastaurin is a protein
kinase-C inhibitor. Both agents are already in studies. Sorafenib is a multikinase inhibitor,
that suppresses angiogenesis by inhibiting VEGFR and PDGFR activities in endothelial cells.
Sorafenib-treated mice showed significant suppression of glioblastoma cell proliferation, in‐
creased apoptosis and autophagy, and reduction of angiogenesis in vivo, phase II trials of
sorafenib in patients with malignant gliomas were inducted. Imatinib is a kinase inhibitor
of PDGFR, c-kit, and bcr-abl. In vitro studies of imatinib on glioma cell proliferation de‐
scribe, that it is cytostatic agent at low concentration whereas at high concentrations it has
cytotoxic effect. Imatinib monotherapy against malignant gliomas has failed to show any
significant clinical benefits probable because of the moderate drug penetration across BBB
and the inhibition of PDGFR alone can be insufficient to inhibit growth of malignant glio‐
mas. In spite of these its use in combination therapy is still an interesting theme. [204-211]
8.3. Other target molecules for anti-angiogenic therapy
Tenascin-C is mainly expressed in hyperplastic vessels and it promotes migration of endo‐
thelial cells in astrocytic tumors. Therefore, blocking tenascin with an antibody to inhibit an‐
giogenesis seems biologically reasonable, so a tenascin-specific antibody radiolabeled with
I-131 was tested in patients with high-grade gliomas. The phase II studies with tenascin-
blocking antibody in malignant glioma reported about a slight increase in survival time.
[101, 195, 212-214]
Another ECM protein that has anti-angiogenic effect in glioma is secreted protein acidic and
rich in cysteine (SPARC), also known as osteonectin or BM-40. Osteonectin takes part in a
number of basic biologic functions, including migration, proliferation, and survival. Expres‐
sion of SPARC in the nervous system is restricted normally to the angiogenic microvascula‐
ture, such as in the region of locus coeruleus and retinal astrocytes, but is not expressed in
the cerebral cortex. In contrast, osteonectin is present in both tumor cells and endothelial
cells in gliomas of all grades, and it is also expressed by endothelial cells and astrocytes in
the adjacent tissue. Osteonectin suppresses tumor angiogenesis via inhibition of VEGF ex‐
pression and secretion. [215-221]
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8.4. Endogenous anti-angiogenic factors
A number of endogenous anti-angiogenic factors have been described that play pivotal role
in tumor angiogenesis. Identifying these factors could offer some anti-cancer agent for neu‐
ro-oncological therapies. One of the best known endogenous anti-angiogenic proteins is an‐
giostatin. It is mainly derived from degradation of plasminogen by proteases cathepsin-D
and MMPs. In vivo studies in mice proved that angiostatin inhibits glioma angiogenesis and
growth. The thrombospondins (TSPs) are another family of proteins that serves as an anti-
angiogenic factor. In normal tissue TSP1 is produced by platelets, endothelial cells, and
smooth muscle cells. Similar to angiostatin, endostatin is also an anti-angiogenic molecule
created in glioblastoma basement membrane by proteolytic cleavage of collagen-18 by elas‐
tase, cathepsin-L, and specific MMPs. The endostatin-mediated signaling has more angio‐
genic inhibitory mechanism by binding to a5b1 integrin, inhibition of VEGF-R2, reduction of
focal adhesion kinase-mediated endothelial cell migration, and suppression of pro-angio‐
genic MMP-2. A further factor is the angiogenesis inhibitor-1 (BAI1), also known as vascu‐
lostatin, that is produced only in glial cells and neurons of normal brain but not in blood
vessels. Since vasculostatin is defnietly reduced in glioblastomas, its role in suppressing an‐
giogenesis is glioma is strongly supposed. [222-231]
9. Conclusion
There are no simple and evidently succesful protocols for therapy of primary brain tumors.
The intensive proliferation activity, the significant peritumoral infiltration and increased an‐
giogenesis altogether are responsible for the extremely high recurrence rate of gliomas. The
failure of recently administered chemotherapy arises the requirement of combination thera‐
py. Thus besides searching a highly specific tumor marker, establishing the molecular spec‐
trum of these tumors can be suggested. Supporting this theory, the mRNA expression
pattern of the invasion-related molecules was found to be highly specific for various differ‐
ent histological tumor groups. So determination of the genetic signature of invasion of a
glioma is thought to help in screening exact molecules as targets for individual chemothera‐
py. [89] Furthermore, complexity of oncotherapy with combination of antiproliferation, anti‐
invasive and antiangiogenic drugs could bring benefits in treatment effectiveness against
brain tumors in the future.
Author details
Almos Klekner
Department of Neurosurgery, University of Debrecen, Medical and Health Science Centre,
Hungary




[1] Burger PC, Scheithauer BW. Tumors of the central nervous system. Atlas of Tumor
Pathology, third series, fascicle 1994; 10: 349-369
[2] Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer
BW, Kleihues P. The 2007 WHO Classification of Tumours of the Central Nervous
System. Acta Neuropathol 2007; 114: 197-109
[3] Miliaras G, Tsitsopoulos PP, Markoula S, Kyritsis A, Polyzoidis KS, Malamou-Mitsi
V. Multifocal glioblastoma with remote cutaneous metastasis: a case report and re‐
view of the literature. Cen Eur Neurosurg 2009; 70: 39-42
[4] Czirok A, Zamir EA, Filla MB, Little CD, Rongish BJ.Extracellular matrix macroas‐
sembly dynamics in early vertebrate embryos. Curr Top Dev Biol 2006; 73: 237-258
[5] Hirose J, Kawashima H, Yoshie O,Tashiro K, Miyasaka M. Versican interacts with
chemokines and modulates cellular responses. J Biol Chem 2001; 276: 5228-5234
[6] Jung S, Moon KS, Kim ST, Ryu HH, Lee YH, Jeong YI, Jung TY, Kim IY, Kim KK,
Kang SS. Increased expression of intracystic matrix metalloproteinases in brain tu‐
mors: relationship to the pathogenesis of brain tumor-associated cysts and peritu‐
moral edema. J Clin Neurosci 2007; 14:1192-1198
[7] Leivonen M, Lundin J, Nordling S, von Boguslawski K, Haglund C.Prognostic Value
of Syndecan-1 Expression in Breast Cancer. Oncology 2004; 67: 11-18
[8] Pakula R, Melchior A, Denys A, Vanpouille C, Mazurier J, Allain F. Syndecan- /
CD147 association is essential for cyclophilin B-induced activation of p44/42 mito‐
gen-activated protein kinases and promotion of cell adhesion and chemotaxis. Glyco‐
biology 2007; 17:492-503
[9] Shibata Sh, Fukada K, Suzuki Sh, Ogawa T, Yamashita Y. Histochemical localisation
of versican, aggrecan and hyaluronan in the developing condylar cartilage of the fe‐
tal rat mandible. J Anat 2001; 198: 129-135
[10] Bellail AC, Hunter SB, Brat DJ, Tan C, Van Meir EG. Microregional extracellular ma‐
trix heterogeneity in brain modulates glioma cell invasion. Int J Biochem Cell Biol
2004; 36:1046–1069
[11] Gladson CL. The extracellular matrix of gliomas: modulation of cell function. J Neu‐
ropathol Exp Neurol 1999; 58:1029–1040
[12] Goldbrunner RH, Bernstein JJ, Tonn JC. Cell-extracellular matrix interaction in glio‐
ma invasion. Acta Neurochir (Wien) 1999; 141:295–305
[13] Nicholson C, Sykova. Extracellular space structure revealed by diffusion analysis.
Trends Neurosci 1998; 21:207–215
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications20
[14] Novak U, Kaye AH. Extracellular matrix and the brain: components and function. J
Clin Neurosci 2000; 7:280–290
[15] Paulus W. Brain extracellular matrix, adhesion molecules and glioma invasion. In:
Mikkelsen T, Bjerkvig R, Laerum OD, Rosenblum ML (eds) Brain tumor invasion: bi‐
ological, clinical and therapeutic considerations. Wiley-Liss, New York, 1998; pp 301–
322
[16] Zamecnik J, Vargova L, Homola A, Kodet R, Sykova E. Extracellular matrix and dif‐
fusion barriers in human astrocytic tumors. Neuropathol Appl Neurobiol 2004;
30:338–350
[17] Langley RR, Fidler IJ. The seed and soil hypothesis revisited - the role of tumor–stro‐
ma interactions in metastasis to different organs. Int J Cancer 2011; 128: 2527–2535.
[18] Kalluri R. Basement membranes: structure, assembly and role in tumour angiogene‐
sis. Nature Rev Cancer 2003; 3: 422–433.
[19] Rougon G, Hobert O. New insights into the diversity and function of neuronal im‐
munoglobulin superfamily molecules. Annu Rev Neurosci 2003; 26: 207–238.
[20] Robinson EE, Zazzali KM, Corbett SA, et al . Alpha5beta1 integrin mediates strong
tissue cohesion. J Cell Sci 2003; 116: 377–386.
[21] Humphries JD, Byron A, Humphries MJ. Integrin ligands at a glance. J Cell Sci 2006;
119: 3901–3903.
[22] Schmidt S, Friedl P. Interstitial cell migration: integrin-dependent and alternative ad‐
hesion mechanisms. Cell Tissue Res 2010; 339:83–92.
[23] Anthis NJ, Campbell ID. The tail of integrin activation. Trends Biochem Sci 2011; 36:
191–198.
[24] Schweitzer T, Vince GH, Herbold C, et al . Extraneural metastases of primary brain
tumors. J Neurooncol 2001; 53: 107–114.
[25] Shapiro L, Love J, Colman DR. Adhesion molecules in the nervous system: structural
insights into function and diversity. Annu Rev Neurosci 2007; 30: 451–474.
[26] Gingras MC, Roussel E, Bruner JM, et al . Comparison of cell adhesion molecule ex‐
pression between glioblastoma multiforme and autologous normal brain tissue. J
Neuroimmunol 1995; 57:143–153.
[27] Calogero A, Pavoni E, Gramaglia T, et al . Altered expression of alpha-dystroglycan
subunit in human gliomas. Cancer Biol Ther 2006; 5: 441–448.
[28] Paulus W, Baur I, Schuppan D, et al . Characterization of integrin receptors in normal
and neoplastic human brain. Am J Pathol 1993; 143: 154–163.
[29] Kawataki T, Yamane T, Naganuma H, et al . Laminin isoforms and their integrin re‐
ceptors in glioma cell migration and invasiveness: evidence for a role of alpha5-lami‐
nin(s) and alpha3beta1 integrin. Exp Cell Res 2007; 313: 3819–3831.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
21
[30] Jahn O, Tenzer S, Werner HB. Myelin proteomics: molecular anatomy of an insulat‐
ing sheath. Mol Neurobiol 2009; 40: 55–72.
[31] Nakada M, Kita D, Futami K, et al . Roles of membrane type 1 matrix metalloprotei‐
nase and tissue inhibitor of metalloproteinases 2 in invasion and dissemination of
human malignant glioma. J Neurosurg 2001; 94: 464–473.
[32] Leavesley DI, Ferguson GD, Wayner EA et al. Requirement of the integrin beta 3 sub‐
unit for carcinoma cell spreading or migration on vitronectin and fibrinogen. J Cell
Biol 1992; 117:1101–1107
[33] Platten M, Wick W, Wild-Bode C et al. Transforming growth factors beta(1) (TGF-be‐
ta(1)) and TGF-beta(2) promote glioma cell migration via up-regulation of al‐
pha(V)beta(3) integrin expression. Biochem Biophys Res Commun 2000; 268:607–611
[34] Guan JL, Shalloway D: Regulation of focal adhesionassociated protein tyrosine kin‐
ase by both cellular adhesion and oncogenic transformation. Nature 358: 690–692,
1992
[35] Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu E T, Cance W G:
Overexpression of the focal adhesion inase (p125FAK) in invasive human tumors.
Cancer Res 55: 2752–2755, 1995
[36] Jones G, Machado J Jr, Merlo A: Loss of focal adhesion kinase (FAK) inhibits epider‐
mal growth factor receptordependent migration and induces aggregation of nh(2)-
terminal FAK in the nuclei of apoptotic glioblastoma cells. Cancer Res, 61: 4978–4981,
2001
[37] Zagzag D, Friedlander DR, Margolis B, Grumet M, Semenza GL, Zhong H, Simons
JW, Holash. J, Wiegand, SJ, Yancopoulos GD: Molecular events implicated in brain
tumor angiogenesis and invasion. Pediatr Neurosurg 33: 49–55, 2000
[38] Cary LA, Guan JL: Focal adhesion kinase in integrinmediated signaling. Front: Bio‐
sci, 4: D102–113, 1999
[39] Hauck CR, Hsia DA, Schlaepfer DD: The focal adhesion kinase – a regulator of cell
migration and invasion. IUBMB Life 53: 115–119, 2002
[40] Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY: Control of adhesion-dependent cell
survival by focal adhesion kinase. J Cell Biol 134: 793–799, 1996
[41] Xiong W, Parsons JT: Induction of apoptosis after expression of PYK2, a tyrosine kin‐
ase structurally relatedto focal adhesion kinase. J Cell Biol 139: 529–539, 1997
[42] Graham CH, Connelly I, MacDougall JR, Kerbel RS, Stetler-Stevenson WG, Lala PK:
Resistance of malignant trophoblast cells to both the anti-proliferative and antiinva‐
sive effects of transforming growth factor-beta. Exp Cell Res 214: 93–99, 1994
[43] Merzak A, Koocheckpour S, Pilkington GJ: CD44 mediates human glioma cell adhe‐
sion and invasion in vitro. Cancer Res 54: 3988–3992, 1994
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications22
[44] Prag S, Lepekhin EA, Kolkova K, Hartmann-Petersen R, Kawa A, Walmod PS, Bel‐
man V, Gallagher H, C, Berezin V, Bock E, Pedersen N: NCAM regulates cell motili‐
ty. J Cell Sci 115: 283–292, 2002
[45] Hikawa T, Mori T, Abe T, Hori S: The ability in adhesion and invasion of drug-resist‐
ant human glioma cells. J Exp Clin Cancer Res 19: 357–362, 2000
[46] Varga I, Hutóczki G, Petrás M, Kenyeres A, Scholtz B, Mikó E, Hanzély Z, Tóth J,
Bognár L, Zahuczky G, Klekner A: Expression of invasion-related extracellular ma‐
trix molecules in human glioblastoma versus intracerebral lung adenocarcinoma
metastasis. Cen Eur Neurosurg, 2010 Nov;71(4):173-80
[47] Naor D, Wallach-Dayan SB, Zahalka MA, et al . Involvement of CD44, a molecule
with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008; 18: 260–267.
[48] Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regu‐
lators. Nature RevMol Cell Biol 2003; 4: 33–45.
[49] Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nature reviews.
Cancer.2004;4:528–539.
[50] Toole BP. Hyaluronan promotes the malignant phenotype. Glycobiology. 2002;12:37–
42.
[51] Day AJ, Prestwich GD. Hyaluronan-binding proteins: tying up the giant. J Biol
Chem.2002;277:4585–4588.
[52] Tsukita S, Oishi K, Sato N, Sagara J, Kawai A. ERM family members as molecular
linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J
Cell Biol. 1994;126:391–401.
[53] Lokeshwar VB, Fregien N, Bourguignon LY. Ankyrin-binding domain of CD44
(GP85) is required for the expression of hyaluronic acid-mediated adhesion function.
J Cell Biol. 1994;126:1099–1109.
[54] Li H, Guo L, Li JW, Liu N, Qi R, Liu J. Expression of hyaluronan receptors CD44 and
RHAMM in stomach cancers: relevance with tumor progression. Int J Oncol.
2000;17:927–932.
[55] Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nature reviews.
Cancer.2004;4:528–539.
[56] Ponta H, Sherman L, Herrlich P. CD44: from adhesion molecules to signalling regula‐
tors. Nature Rev Mol Cell Biol. 2003;4:33–45.
[57] Fieber C, Plug R, Sleeman J, Dall P, Ponta H, Hofmann M. Characterisation of the
murine gene encoding the intracellular hyaluronan receptor IHABP (RHAMM)
Gene. 1999;226:41.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
23
[58] Thorne RF, Legg JW, Isacke CM. The role of the CD44 transmembrane and cytoplas‐
mic domains in coordinating adhesive and signaling events. J Cell Sci. 2004;117:373–
380.
[59] Morgan MR, Humphries MJ, Bass MD. Synergistic control of cell adhesion by integ‐
rins and syndecans. Nature Rev Mol Cell Biol 2007; 8: 957–969.
[60] Xian X, Gopal S, Couchman JR. Syndecans as receptors and organizers of the extrac‐
ellular matrix. Cell Tissue Res 2010; 339: 31–46.
[61] Kim C W et al., “Members of the syndecan family of heparan sulfate proteoglycans
are expressed in distinct cell-, tissue-, and development-specific patterns. Molecular
Biology of the Cell 5, no. 7 (July 1994): 797–805.
[62] Anttonen A et al., “Syndecan-1 expression has prognostic significance in head and
neck carcinoma. British Journal of Cancer 79, no. 3-4 (February 1999): 558–564.
[63] Maret D, Gruzglin E, Sadr MS, Siu V, Shan W, Koch AW, Seidah NG, Del Maestro
RF, Colman DR. Surface expression of precursor N-cadherin promotes tumor cell in‐
vasion. Neoplasia. 2010 Dec;12(12):1066-80.
[64] Kohutek ZA, diPierro CG, Redpath GT, Hussaini IM. ADAM-10-mediated N-cadher‐
in cleavage is protein kinase C-alpha dependent and promotes glioblastoma cell mi‐
gration. J Neurosci. 2009 Apr 8;29(14):4605-15.
[65] Nollet F, Kools P, van Roy F: Phylogenetic analysis of the cadherin superfamily al‐
lows identification of six major subfamilies besides several solitary members. J Mol
Biol 299: 551–572, 2000
[66] Shapiro L, Weis WI. Structure and biochemistry of cadherins and catenins. Cold
Spring Harbor Perspect Biol 2009; 1: a003053.
[67] Shapiro L, Love J, Colman DR. Adhesion molecules in the nervous system: structural
insights into function and diversity. Annu Rev Neurosci 2007; 30: 451–474.
[68] Nollet F, Kools P, van Roy F. Phylogenetic analysis of the cadherin superfamily al‐
lows identification of six major subfamilies besides several solitary members. JMol
Biol 2000; 299: 551–572.
[69] Bozzi M, Morlacchi S, Bigotti MG, et al . Functional diversity of dystroglycan. Matrix
Biol 2009; 28: 179–187.
[70] Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, Petrucci
TC. Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol
Ther. 2006 Apr;5(4):441-8.
[71] Gee SH, Montanaro F, Lindenbaum MH, Carbonetto S. Dystroglycan-alpha, a dystro‐
phin-associated glycoprotein, is a functional agrin receptor. Cell 1994; 77 (5): 675–86.
[72] Pankov R, Yamada KM. Fibronectin at a glance. J Cell Sci 2002; 115 (Pt 20): 3861–3
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications24
[73] Hu B., Kong L. L., Matthews R. T., Viapiano M. S. The proteoglycan brevican binds
to fibronectin after proteolytic cleavage and promotes glioma cell motility. J. Biol.
Chem. 2008; 283(36):24848-59
[74] Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K: Chondroitin sulfate pro‐
teoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to
cellular fibronectin. J Biol Chem 1986, 261(29):13526-13535.
[75] Timpl R et al. Laminin – a glycoprotein from basement membranes. J Biol Chem
1979; 254 (19): 21. 9933
[76] Guo P, Imanishi Y, Cackowski FC, et al. Up-regulation of angiopoietin- 2, matrix
metalloprotease-2, membrane type 1 metalloprotease, and laminin 5 gamma 2 corre‐
lates with the invasiveness of human glioma. Am J Pathol 2005; 166:877– 890
[77] Aguiar CB, Lobão-Soares B, Alvarez-Silva M, Trentin AG.Glycosaminoglycans mod‐
ulate C6 glioma cell adhesion to extracellular matrix components and alter cell prolif‐
eration and cell migration. BMC Cell Biol. 2005 Aug 19;6:31.
[78] Sanes JR, Lichtmann JW: Induction, assembly, maturation and maintenance of a post‐
synaptic apparatus. Nat Rev Neurosci 2001; 2(11): 791-805
[79] Delpech B, Maingonnat C, Girard N, Chauzy C, Maunoury R, Olivier A, Tayot J,
Creissard P. Hyaluronan and hyaluronectin in the extracellular matrix of human
brain tumour stroma. Eur J Cancer 1993; 29A:1012–1017
[80] Sadeghi N, Camby I, Goldman S, Gabius HJ, Baleriaux D, Salmon I, Decaesteckere C,
Kiss R, Metens T. Effect of hydrophilic components of the extracellular matrix on
quantifiable diffusion-weighted imaging of human gliomas: preliminary results of
correlating apparent diffusion coefficient values and hyaluronan expression level.
AJR Am J Roentgenol 2003; 181:235–241
[81] Itano N. Simple primary structure, complex turnover regulation and multiple roles
of hyaluronan. J Biochem 2008; 144: 131–137.
[82] Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer
Biol 2011; 21: 107–112.
[83] Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nature Reviews.
Cancer.2004;4:528–539.
[84] Kim MS, Park MJ, Moon EJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES, Lee SH. Hya‐
luronic acid induces osteopontin via the phosphatidylinositol 3-kinase/AKT pathway
to enhance the motility of human glioma cells. Cancer Res. 2005;65:686–691.
[85] Viapiano MS, Matthews RT. From barriers to bridges: chondroitin sulfate proteogly‐
cans in Neuropathology. Trends Mol Med 2006; 12: 488–496.
[86] Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life
Sci 2000; 57: 276–289.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
25
[87] Nutt CL, Matthews RT, Hockfield S. Glial tumor invasion: a role for the upregulation
and cleavage of BEHAB/brevican. Neuroscientist 2001; 7: 113-122
[88] Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT. Novel tumor-specific
isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res
2005; 65: 6726-6733
[89] Varga, G. Hutóczki, Cs. D. Szemcsák, G. Zahuczky, J. Tóth, Zs. Adamecz, A. Ken‐
yeres, L. Bognár, Z. Hanzély, A. Klekner: Brevican, neurocan, tenascin-C and versi‐
can are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol
Oncol Res, Pathol Oncol Res. 2012 Apr;18(2):413-20.
[90] Akita K., Toda M., Hosoki Y., Inoue M., Fushiki S., Oohira A., Okayama M., Yama‐
shina I., Nakada H. Heparan sulphate proteoglycans interact with neurocan and pro‐
mote neurite outgrowth from cerebellar granule cells. Biochem J. 2004; 383(Pt 1):
129-38
[91] Kim C. H., Bak K. H., Kim Y. S., Kim J. M., Ko Y., Oh S. J., Kim K. M., Hong E. K.
Expression of tenascin-C in astrocytic tumors: its relevance to proliferation and an‐
giogenesis. Surg. Neurol. 2000; 54(3):235-40
[92] Swindle C. S., Tran K. T., Johnson T. D., Banerjee P., Mayes A. M., Griffith L., Wells
A. Epidermal growth factor (EGF)-like repeats of human tenascin-C as ligands for
EGF receptor. J. Cell Biol. 2001; 154(2):459-68
[93] Fischer D., Brown-Lüdi M.,Schulthess T., Chiquet-Ehrismann R. Concerted action of
tenascin-C domains in cell adhesion, anti-adhesion and promotion of neurite out‐
growth. J. Cell Sci. 1997; 110(Pt13):1513-22
[94] Hirata E., Arakawa Y., Shirahata M., Yamaguchi M., Kishi Y., Okada T., Takahashi J.
A., Matsuda M., Hashimoto N. Endogenous tenascin-C enhances glioblastoma inva‐
sion with reactive change of surrounding brain tissue. Cancer Sci. 2009; 100(8):1451-9
[95] Maris C., Rorive S., Sandras F., D'Haene N., Sadeghi N., Bièche I., Vidaud M., Deca‐
estecker C., Salmon I. Tenascin-C expression relates to clinicopathological features in
pilocytic and diffuse astrocytomas. Neuropathol. Appl. Neurobiol. 2008; 34(3):316-29
[96] Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v be‐
ta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest 1991;
88:1924– 1932
[97] Joester A, Faissner A. The structure and function of tenascin in the nervous system.
Matrix Biol 2001; 20:13–22
[98] Mahesparan R, Read TA, Lund-Johansen M, Skaftnesmo KO, Bjerkvig R, Engebraat‐
en O. Expression of extracellular matrix components in a highly infiltrative in vivo
glioma model. Acta Neuropathol 2003; 105:49–57
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications26
[99] Oz B, Karayel FA, Gazio NL, Ozlen F, Balci K. The distribution of extracellular matrix
proteins and CD44S expression in human astrocytomas. Pathol Oncol Res 2000;
6:118–124
[100] Zamecnik J, Chanova M, Tichy M, Kodet R. Distribution of the extracellular matrix
glycoproteins in ependymomas— an immunohistochemical study with follow-up
analysis. Neoplasma 2004; 51:214–222
[101] Zagzag D, Friedlander DR, Dosik J, Chikramane S, Chan W, Greco MA, Allen JC,
Dorovini-Zis K, Grumet M: Tenascin-C expression by angiogenic vessels in human
astrocytomas and by human brain endothelial cells in vitro. Cancer Res, 56: 182–189,
1996
[102] Kostianovsky M, Greco MA, Cangiarella J, Zagzag D: Tenascin-C expression in ultra‐
structurally defined angiogenic and vasculogenic lesions. Ultrastruct Pathol 21: 537–
544, 1997
[103] Zagzag D, Capo V: Angiogenesis in the central nervous system: a role for vascular
endothelial growth factor/vascular permeability factor and tenascin-C. Common mo‐
lecular effectors in cerebral neoplastic, and non-neoplastic ‘angiogenic diseases’. His‐
tol Histopathol 17: 301– 321, 2002
[104] Plopper GE, McNamee HP, Dike LE, Bojanowski K, Ingber DE: Convergence of in‐
tegrin and growth factor receptor signaling pathways within the focal adhesion com‐
plex. Mol Biol Cell 6: 1349–1365, 1995
[105] Mauri P, Scarpa A, Nascimbeni AC, Benazzi L, Parmagnani E, Mafficini A, Della Pe‐
ruta M, Bassi C, Miyazaki K, Sorio C: Identification of proteins released by pancreatic
cancer cells by multidimensional protein identification technology: a strategy for
identification of novel cancer markers. Faseb J 2005, 19(9):1125-1127.
[106] Voutilainen K, Anttila M, Sillanpaa S, Tammi R, Tammi M, Saarikoski S, Kosma VM:
Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic fac‐
tors and prognosis. Int J Cancer 2003, 107(3):359-364.
[107] Aspberg A, Binkert C, Ruoslahti E: The versican C-type lectin domain recognizes the
adhesion protein tenascin-R. Proc Natl Acad Sci U S A 1995, 92(23):10590-10594.
[108] Aspberg A, Adam S, Kostka G, Timpl R, Heinegard D: Fibulin-1 is a ligand for the C-
type lectin domains of aggrecan and versican. J Biol Chem 1999, 274(29):20444-20449.
[109] Isogai Z, Aspberg A, Keene DR, Ono RN, Reinhardt DP, Sakai LY: Versican interacts
with fibrillin-1 and links extracellular microfibrils to other connective tissue net‐
works. J Biol Chem 2002, 277(6):4565-4572.
[110] Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, Miyasaka M: Binding of
a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-
selectin, and CD44. J Biol Chem 2000, 275(45):35448-35456.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
27
[111] Perides G, Asher RA, Lark MW, Lane WS, Robinson RA, Bignami A: Glial hyaluro‐
nate-binding protein: a product of metalloproteinase digestion of versican? Biochem
J 1995, 312 ( Pt 2):377-384.
[112] Van Lint P, Libert C (December 2007). Chemokine and cytokine processing by matrix
metalloproteinases and its effect on leukocyte migration and inflammation. J. Leu‐
koc. Biol. 82 (6): 1375–81.
[113] Wild-Bode C, Weller M, Wick W. Molecular determinants of glioma cell migration
and invasion. J Neurosurg 2001; 94:978–984
[114] Demchik LL, Sameni M, Nelson K, Mikkelsen T, Sloane BF: Cathepsin B and glioma
invasion. Int J Dev Neurosci 17: 483–494, 1999
[115] Rempel SA, Rosenblum ML, Mikkelsen T, Yan. PS, Ellis KD, Golembieski WA, Same‐
ni M, Rozhin J, Ziegler G, Sloane BF: Cathepsin B expression and localization in glio‐
ma progression and invasion. Cancer Res 54: 6027–6031, 1994
[116] Sivaparvathi M, Sawaya R, Wang SW, Rayford A, Yamamoto M, Liotta LA, Nicolson
GL, Rao JS: Overexpression and localization of cathepsin B during the progression of
human gliomas. Clin Exp Metastasis 13: 49–56, 1995
[117] Mohanam S, Jasti SL, Kondraganti SR, Chandrasekar N, Lakka SS, Kin Y, Fuller GN,
Yung AW, Kyritsis AP, Dinh DH; Olivero WC, Gujrati M, Ali-Osman F, Rao JS:
Down-regulation of cathepsin B expression impairs the invasive and tumorigenic po‐
tential of human glioblastoma cells. Oncogene 20: 3665–3673, 2001
[118] Levicar N, Dewey RA, Daley E, Bates TE, Davies D, Kos J, Pilkington GJ, and Lah TT:
Selective suppression of cathepsin L by antisense cDNA impairs human braintumor
cell invasion in vitro and promotes apoptosis. Cancer Gene Then 10: 141–151, 2003
[119] Manabu O, Tomotsugu I,Kazuhiko K,Isao D. Angiogenesis and invasion in glioma.
Brain Tumor Pathol 2011; 28:13–24
[120] Calogero A, Pavoni E, Gramaglia T, D'Amati G, Ragona G, Brancaccio A, Petrucci
TC. Altered expression of alpha-dystroglycan subunit in human gliomas. Cancer Biol
Ther. 2006 Apr;5(4):441-8.
[121] Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion.
J Neurooncol 2004; 70:217–228
[122] Goodenough DA, Goliger JA, Paul DL. Connexins, connexons, and intercellular com‐
munication. Annu Rev Biochem 1996; 65:475–502
[123] Soroceanu L, Manning TJ Jr, Sontheimer H. Reduced expression of connexin-43 and
functional gap junction coupling in human gliomas. Glia 2001; 33:107–117
[124] Beadle C, Assanah MC, Monzo P, Vallee R, Rosenfeld SS, Canoll P. The role of myo‐
sin II in glioma invasion of the brain. Mol Biol Cell 2008;19:3357–3368.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications28
[125] Tonn JC, Wunderlich S, Kerkau S, Klein CE, Roosen K: Invasive behaviour of human
gliomas is mediated by interindividually different integrin patterns. AnticancerRes
18: 2599–2605, 1998
[126] Taga T, Suzuki A, Gonzalez-Gomez I, Gilles FH, Stins M, Shimada H, Barsky L,
Weinberg KI, Laug WE: alpha v- Integrin antagonist EMD 121974 induces apoptosis
in brain tumor cells growing on vitronectin and tenascin. Int J Cancer 98: 690–697,
2002
[127] MacDonald TJ, Taga T, Shimada H, Tabrizi, P, Zlokovic BV, Cheresh DA, Laug WE:
Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v)
integrin antagonist. Neurosurgery 48: 151–157 2001
[128] Etienne-Manneville S, Hall A: Rho GTPases in cell biology. Nature 420; 629–635, 2002
[129] Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide,
an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblasto‐
ma multiforme. J Clin Oncol 2008;26:5610 –5617.
[130] Arslan F, Bosserhoff AK, Nickl-Jockschat T, Doerfelt A, Bogdahn U, Hau P: The role
of versican isoforms V0/V1 in glioma migration mediated by transforming growth
factor-beta2. Br J Cancer 2007, 96(10):1560-1568.
[131] Syrokou A, Tzanakakis GN, Hjerpe A, Karamanos NK: Proteoglycans in human ma‐
lignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin
and platelet-derived growth factors involves receptors with tyrosine kinase activity.
Biochimie 1999, 81(7):733-744.
[132] Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, Lee DY, Seth A, Yee AJ:
Versican G3 promotes mouse mammary tumor cell growth, migration, and metasta‐
sis by influencing EGF receptor signaling. PLoS One, 5(11):e13828
[133] Casey RC, Koch KA, Oegema TR, Jr., Skubitz KM, Pambuccian SE, Grindle SM, Sku‐
bitz AP: Establishment of an in vitro assay to measure the invasion of ovarian carci‐
noma cells through mesothelial cell monolayers. Clin Exp Metastasis 2003, 20(4):
343-356
[134] Nakamura JL, Haas-Kogan DA, Pieper RO: Glioma invasiveness responds variably
to irradiation in a co-culture model. Int J Radiat Oncol Biol Phys 2007, 69(3):880-886.
[135] Almholt K, Juncker-Jensen A, Laerum OD, Dano K, Johnsen M, Lund LR, Romer J:
Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in
the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther 2008, 7(9):
2758-2767.
[136] Vankemmelbeke MN, Jones GC, Fowles C, Ilic MZ, Handley CJ, Day AJ, Knight CG,
Mort JS, Buttle DJ: Selective inhibition of ADAMTS-1, -4 and -5 by catechin gallate
esters. Eur J Biochem 2003, 270(11):2394-2403
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
29
[137] Schonherr E, Kinsella MG, Wight TN: Genistein selectively inhibits platelet-derived
growth factor-stimulated versican biosynthesis in monkey arterial smooth muscle
cells. Arch Biochem Biophys 1997, 339(2):353-361.
[138] Evanko SP, Angello JC, Wight TN: Formation of hyaluronan- and versican-rich peri‐
cellular matrix is required for proliferation and migration of vascular smooth muscle
cells. Arterioscler Thromb Vasc Biol 1999, 19(4):1004-1013.
[139] Ween MP, Hummitzsch K, Rodgers RJ, Oehler MK, Ricciardelli C: Versican induces a
pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyalur‐
onan oligosaccharides. Clin Exp Metastasis, 28(2):113-125.
[140] Zeng C, Toole BP, Kinney SD, Kuo JW, Stamenkovic I: Inhibition of tumor growth in
vivo by hyaluronan oligomers. Int J Cancer 1998, 77(3):396-401.
[141] Kim MS, Park MJ, Kim SJ, Lee CH, Yoo H, Shin SH, Song ES, Lee SH. Emodin sup‐
presses hyaluronic acid-induced MMP-9 secretion and ivnasion of gliomas cells. Int J
Oncol. 2005;27:839–846.[
[142] Arata Watanabe A, Mabuchi T, Satoh E, Furuya K, Zhang L, Maeda S, Maeda S, Na‐
ganuma H. Expression of syndecans, a heparin sulfate proteoglycan, in malignant
gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 ex‐
pression. J Neurooncol. 2006;77:25–32.
[143] Levin VA, Phuphanich S, Yung WK et al. Randomized, double-blind, placebo-con‐
trolled trial of marimastat in glioblastoma multiforme patients following surgery and
irradiation. J Neurooncol 2006; 78:295–302
[144] Groves MD, Puduvalli VK, Hess KR et al. Phase II trial of temozolomide plus the ma‐
trix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblasto‐
ma multiforme. J Clin Oncol 2002; 20:1383–1388
[145] Sakariassen PO, Prestegarden L, Wang J et al.Angiogenesis- independent tumor
growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006; 103:16466–
16471
[146] Wang D, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogene‐
sis in malignant glioma tumors. Brain Pathol 2005;15:318 –326.
[147] Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev
Cancer 2004;4:437– 447.
[148] Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differen‐
tially expressed in normal brain and glioblastoma independently of p53 expression.
Am J Pathol 2003; 162:19 –27.
[149] Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in glio‐
magenesis and tumoral angiogenesis. Neuro Oncol 2005;7:122–133.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications30
[150] Desbaillets I, Diserens AC, de Tribolet N, Hamou MF, Van Meir EG. Regulation of
interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Onco‐
gene 1999;18:1447–1456.
[151] Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D. Angiogenesis in gliomas: bi‐
ology and molecular pathophysiology. Brain Pathol 2005;15:297–310.
[152] Kaur B, Tan C, Brat DJ, Post DE, Van Meir EG. Genetic and hypoxic regulation of an‐
giogenesis in gliomas. J Neurooncol 2004;70:229 –243.
[153] Aghi M, Chiocca EA. Contribution of bone marrow-derived cells to blood vessels in
ischemic tissues and tumors. Mol Ther 2005; 12:994 –1005.
[154] Jouanneau E. Angiogenesis and gliomas: current issues and development of surro‐
gate markers. Neurosurgery 2008;62:31–50.
[155] Aghi M, Cohen KS, Klein RJ, Scadden DT, Chiocca EA. Tumor stromal-derived fac‐
tor-1 recruits vascular progenitors to mitotic neovasculature, where microenviron‐
ment influences their differentiated phenotypes. Cancer Res 2006;66:9054 –9064.
[156] Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-
derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Can‐
cer Cell 2008;13: 206–220.
[157] Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance.
Neuro Oncol 2005;7:452– 464.
[158] Reiss Y, Machein MR, Plate KH. The role of angiopoietins during angiogenesis in
gliomas. Brain Pathol 2005;15:311–317.
[159] Zagzag D, Amirnovin R, Greco MA, et al. Vascular apoptosis and involution in glio‐
mas precede neovascularization: a novel concept for glioma growth and angiogene‐
sis. Lab Invest 2000;80: 837–849.
[160] Stratmann A, Risau W, Plate KH. Cell type-specific expression of angiopoietin-1 and
angiopoietin-2 suggests a role in glioblastoma angiogenesis. Am J Pathol
1998;153:1459 –1466.
[161] Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and
growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994 –1998.
[162] Hu B, Guo P, Fang Q, et al. Angiopoietin-2 induces human glioma invasion through
the activation of matrix metalloprotease- 2. Proc Natl Acad Sci U S A 2003;100:8904–
8909.
[163] Rooprai HK, McCormick D. Proteases and their inhibitors in human brain tumours: a
review. Anticancer Res 1997;17:4151– 4162.
[164] Raithatha SA, Muzik H, Rewcastle NB, Johnston RN, Edwards DR, Forsyth PA. Lo‐
calization of gelatinase-A and gelatinase-B mRNA and protein in human gliomas.
Neuro Oncol 2000;2:145– 150.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
31
[165] Rao JS, Yamamoto M, Mohaman S, et al. Expression and localization of 92 kDa type
IV collagenase/gelatinase B (MMP-9) in human gliomas. Clin Exp Metastasis
1996;14:12–18.
[166] Lakka SS, Gondi CS, Rao JS. Proteases and glioma angiogenesis. Brain Pathol
2005;15:327–341
[167] Jouanneau E. Angiogenesis and gliomas: current issues and development of surro‐
gate markers. Neurosurgery 2008;62:31–50.
[168] Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance.
Neuro Oncol 2005;7:452– 464.
[169] Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967–974.
[170] Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic ves‐
sels of glioblastoma tumours. Expert Rev Mol Med 2008;10:e23.
[171] Jouanneau E. Angiogenesis and gliomas: current issues and development of surro‐
gate markers. Neurosurgery 2008;62:31–50.
[172] Herold-Mende C, Mueller MM, Bonsanto MM, Schmitt HP, Kunze S, Steiner HH.
Clinical impact and functional aspects of tenascin-C expression during glioma pro‐
gression. Int J Cancer 2002;98:362–369.
[173] Baluk P, Morikawa S, Haskell A, Mancuso M, McDonald DM. Abnormalities of base‐
ment membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol
2003;163:1801–1815.
[174] Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD. Expression of adhesion mole‐
cules and extracellular matrix proteins in glioblastomas: relation to angiogenesis and
spread. Histopathology 1996;28:521–528.
[175] Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch
during tumorigenesis. Cell 1996;86:353–364.
[176] Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249
–257.
[177] Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a criti‐
cal cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J
Clin Oncol 2002;20: 4368–4380.
[178] Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. En‐
docr Rev 2004;25:581– 611.
[179] Machein MR, Plate KH. VEGF in brain tumors. J Neurooncol 2000;50:109 –120.
[180] Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a po‐
tential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845–
848.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications32
[181] Whitelock JM, Murdoch AD, Iozzo RV, Underwood PA. The degradation of human
endothelial cell-derived perlecan and release of bound basic fibroblast growth factor
by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem 1996;271: 10079–
10086.
[182] Grau SJ, Trillsch F, Herms J, et al. Expression of VEGFR3 in glioma endothelium cor‐
relates with tumor grade. J Neurooncol 2007;82:141–150.
[183] Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT. Angiogene‐
sis in brain tumours. Nat Rev Neurosci 2007;8:610–622.
[184] Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differen‐
tially expressed in normal brain and glioblastoma independently of p53 expression.
Am J Pathol 2003; 162:19 –27.
[185] Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685– 693.
[186] Karcher S, Steiner HH, Ahmadi R, et al. Different angiogenic phenotypes in primary
and secondary glioblastomas. Int J Cancer 2006;118:2182–2189.
[187] Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in glio‐
magenesis and tumoral angiogenesis. Neuro Oncol 2005;7:122–133.
[188] Melder RJ, Koenig GC, Witwer BP, Safabakhsh N, Munn LL, Jain RK. During angio‐
genesis, vascular endothelial growth factor and basic fibroblast growth factor regu‐
late natural killer cell adhesion to tumor endothelium. Nat Med 1996;2:992–997.
[189] Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumoursuppressor protein
ING4 regulates brain tumour growth and angiogenesis. Nature 2004;428:328 –332.
[190] Mamluk R, Klagsbrun M, Detmar M, Bielenberg DR. Soluble neuropilin targeted to
the skin inhibits vascular permeability. Angiogenesis 2005;8:217–227.
[191] Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. Neuropilin-1 is expressed
by endothelial and tumor cells as an isoform-specific receptor for vascular endothe‐
lial growth factor. Cell 1998;92:735–745.
[192] Miao HQ, Klagsbrun M. Neuropilin is a mediator of angiogenesis. Cancer Metastasis
Rev 2000;19:29 –37.
[193] Wang D, Anderson JC, Gladson CL. The role of the extracellular matrix in angiogene‐
sis in malignant glioma tumors. Brain Pathol 2005;15:318 –326.
[194] Castellani P, Viale G, Dorcaratto A, et al. The fibronectin isoform containing the ED-
B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612– 618.
[195] Zagzag D, Shiff B, Jallo GI, et al. Tenascin-C promotes microvascular cell migration
and phosphorylation of focal adhesion kinase. Cancer Res 2002;62:2660 –2668.
[196] Mariani G, Lasku A, Balza E, et al. Tumor targeting potential of the monoclonal anti‐
body BC-1 against oncofetal fibronectin in nude mice bearing human tumor im‐
plants. Cancer 1997;80:2378– 2384.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
33
[197] Fujita M, Khazenzon NM, Ljubimov AV, et al. Inhibition of laminin-8 in vivo using a
novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis
2006;9:183–191.
[198] Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and ad‐
juvant temozolomide for glioblastoma. N Engl J Med 2005; 352:987–996
[199] Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab
and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13:1253–1259.
[200] Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan
in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722– 4729.
[201] Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant glio‐
mas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779 –787.
[202] Chi A, Norden AD, Wen PY. Inhibition of angiogenesis and invasion in malignant
gliomas. Expert Rev Anticancer Ther 2007; 7:1537–1560.
[203] Sathornsumetee S, Cao Y, Marcello JE et al. Tumor angiogenic and hypoxic profiles
predict radiographic response and survival in malignant astrocytoma patients treat‐
ed with bevacizumab and irinotecan. J Clin Oncol 2008; 26:271–278
[204] Roberts WG, Whalen PM, Soderstrom E, et al. Antiangiogenic and antitumor activity
of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res 2005;65:957–
966.
[205] Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyro‐
sine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblas‐
toma patients. Cancer Cell 2007;11:83–95.
[206] Tabatabai G, Frank B, Wick A, et al. Synergistic antiglioma activity of radiotherapy
and enzastaurin. Ann Neurol 2007;61:153–161.
[207] Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor
distribution of temozolomide. Clin Cancer Res 2008;14:1540 –1549.
[208] Wong ML, Prawira A, Kaye AH et al. Tumour angiogenesis: its mechanism and ther‐
apeutic implications in malignant gliomas. J Clin Neurosci 2009; 16:1119–1130
[209] Siegelin MD, Raskett CM, Gilbert CA, Ross AH, Altieri DC (2010) Sorafenib exerts
anti-glioma activity in vitro and in vivo. Neurosci Lett 478:165–170
[210] Ranza E, Mazzini G, Facoetti A, Nano R. In vitro effects of the tyrosine kinase inhibi‐
tor imatinib on glioblastoma cell proliferation. J Neurooncol 2010; 96:349–357
[211] Wen PY, Yung WK, Lamborn KR et al. Phase I/II study of imatinib mesylate for re‐
current malignant gliomas: North American Brain Tumor Consortium Study 2006;
99-08. Clin Cancer Res 12:4899–4907
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications34
[212] Akabani G, Reardon DA, Coleman RE, et al. Dosimetry and radiographic analysis of
131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed pa‐
tients with malignant gliomas: a phase II study. J Nucl Med 2005;46:1042–1051.
[213] Bigner DD, Brown M, Coleman RE et al. Phase I studies of treatment of malignant
gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies an‐
ti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F(ab0)2––a pre‐
liminary report. J Neurooncol 1995; 24:109–122
[214] Reardon DA, Akabani G, Coleman RE et al. Phase II trial of murine (131)I-labeled an‐
titenascin monoclonal antibody 81C6 administered into surgically created resection
cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;
20:1389–1397
[215] Yunker CK, Golembieski W, Lemke N, et al. SPARC-induced increase in glioma ma‐
trix and decrease in vascularity are associated with reduced VEGF expression and se‐
cretion. Int J Cancer 2008;122:2735–2743.
[216] Rempel SA, Golembieski WA, Ge S, et al. SPARC: a signal of astrocytic neoplastic
transformation and reactive response in human primary and xenograft gliomas. J
Neuropathol Exp Neurol 1998;57:1112–1121.
[217] Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell func‐
tion. Curr Opin Cell Biol 2002;14:608–616.
[218] Lane TF, Iruela-Arispe ML, Johnson RS, Sage EH. SPARC is a source of copper-bind‐
ing peptides that stimulate angiogenesis. J Cell Biol 1994;125:929 –943.
[219] Yan Q, Sage EH, Hendrickson AE. SPARC is expressed by ganglion cells and astro‐
cytes in bovine retina. J Histochem Cytochem 1998;46:3–10.
[220] Lane TF, Sage EH. The biology of SPARC, a protein that modulates cell-matrix inter‐
actions. FASEB J 1994;8:163–173.
[221] Anderson JC, McFarland BC, Gladson CL. New molecular targets in angiogenic ves‐
sels of glioblastoma tumours. Expert Rev Mol Med 2008;10:e23.
[222] Kaur B, Brat DJ, Calkins CC, Van Meir EG. Brain angiogenesis inhibitor 1 is differen‐
tially expressed in normal brain and glioblastoma independently of p53 expression.
Am J Pathol 2003; 162:19 –27.
[223] Wahl ML, Kenan DJ, Gonzalez-Gronow M, Pizzo SV. Angiostatin’s molecular mech‐
anism: aspects of specificity and regulation elucidated. J Cell Biochem 2005;96:242–
261.
[224] O’Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor
that mediates the suppression of metastases by a Lewis lung carcinoma. Cell
1994;79:315–328.
[225] Kirsch M, Strasser J, Allende R, Bello L, Zhang J, Black PM. Angiostatin suppresses
malignant glioma growth in vivo. Cancer Res 1998;58:4654–4659.
Brain Tumor Invasion and Angiogenesis
http://dx.doi.org/10.5772/50198
35
[226] Joe YA, Hong YK, Chung DS, et al. Inhibition of human malignant glioma growth in
vivo by human recombinant plasminogen kringles 1-3. Int J Cancer 1999;82:694–699.
[227] Adams JC, Lawler J. The thrombospondins. Int J Biochem Cell Biol 2004;36:961–968.
[228] Strik HM, Weller M, Frank B, et al. Heat shock protein expression in human gliomas.
Anticancer Res 2000;20:4457– 4462.
[229] Folkman J. Antiangiogenesis in cancer therapy—endostatin and its mechanisms of
action. Exp Cell Res 2006;312:594–607.
[230] Heljasvaara R, Nyberg P, Luostarinen J, et al. Generation of biologically active endo‐
statin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp
Cell Res 2005; 307:292–304.
[231] Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, Kalluri R. Human tumstatin
and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v
beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003;100:4766–4771.
Evolution of the Molecular Biology of Brain Tumors and the Therapeutic Implications36
